Product Description
Lurasidone is a medication used in the treatment of schizophrenia and bipolar depression. It is in the benzisothiazole class of medications. (Sourced from: https://www.ncbi.nlm.nih.gov/books/NBK541057/)
Mechanisms of Action: D2 Antagonist,5-HT2A Antagonist,5-HT7 Antagonist,ADRA2A Antagonist,ADRA2C Antagonist,5-HT1A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | China | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Malaysia | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: Bipolar Disorder | Depressive Disorder | Schizophrenia
Known Adverse Events: Depressive Disorder | Schizophrenia | Insomnia
Company: Sunovion
Company Location: MARLBOROUGH MA 01752
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan, Korea
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Bipolar Disorder|Psychotic Disorders|Schizophrenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| jRCT2011210024 | P3 |
Recruiting |
Schizophrenia |
2025-01-31 |
|
| BK-LuD-301 | P3 |
Completed |
Psychotic Disorders|Schizophrenia |
2022-10-26 |
95% |
| CTR20200256 | P3 |
Recruiting |
Bipolar Disorder |
None |